New Protocol Has Streamlined Cancer Drug Administration
A new subcutaneous injection method could reduce treatment time for patients receiving dual EGFR blockade therapy.
Updated on Oct. 6, 2026 in Cancer
A clinical protocol developed by Dr. Edgardo Santos replaces time-intensive intravenous infusions of amivantamab plus lazertinib with a 5-minute subcutaneous injection. This approach aims to simplify the treatment experience for patients undergoing dual EGFR blockade.
Why it matters
The new protocol incorporates structured management for venous thromboembolism and skin toxicity, addressing side effects commonly associated with dual EGFR blockade therapies. By streamlining the delivery process, the method aims to improve patient care efficiency.
The clinical protocol utilizes a 5-minute subcutaneous injection to deliver amivantamab and lazertinib. It introduces standardized prophylactic measures for common treatment-related skin and vascular side effects.
The players
Edgardo Santos
A physician at Starling Oncology who developed the new subcutaneous administration protocol.
The details
The protocol replaces traditional intravenous dosing, which required a split 2-day infusion schedule, with a single subcutaneous injection. To manage treatment-associated toxicities, the regimen includes prophylactic oral anticoagulation for four months and the COCOON skin management strategy. This includes twice-daily oral antibiotics for 12 weeks, ceramide-based moisturizers, and 4% chlorhexidine nail soaks to prevent paronychia.
Timeline
Week 1: Initial dexamethasone dose and start of antibiotic regimen.
First 4 months: Duration of prophylactic-dose oral anticoagulation.
Week 1 through Week 12: Period for oral doxycycline or minocycline treatment.
Week 13 onward: Implementation of daily scalp lotion application.
Health Landscape
This protocol evolves the standard of care for regimens established in the MARIPOSA trial. It moves toward more convenient administration while systematically addressing known toxicity hurdles in dual EGFR blockade.
Patients prescribed amivantamab plus lazertinib should discuss this subcutaneous protocol with their oncologist to determine if it is appropriate for their care plan. It is important to review the full COCOON regimen, including skin and anticoagulation measures, to safely manage potential side effects.
The takeaway
The new subcutaneous administration protocol offers a significantly faster alternative to traditional intravenous infusions for targeted lung cancer therapy. Discuss the specific skin and vascular management steps included in this protocol with your oncology team.
Further reading
Learn more about the latest innovations in Cancer treatment protocols and patient outcomes.
Source note: This article includes information reported by OncLive.
